What We Do Best


New products with a huge commercial potential for CKD treatment and renal lithiasis.

AVEROA’s pipeline is composed of products targeting renal diseases.

 Our lead product, AVA1014, is already registered in major kidney disease markets, including the US, Japan and South Korea, and should be registered by Averoa in Europe. 

With the LUCIOL project, Averoa is working on a breakthrough treatment (AVA2206) with a new mechanism of action for Renal Lithiasis associated with a companion test (AVA2065).

Business Model

We intend to enhance our product portfolio with complementary products

By identifying and in-licensing late-stage drugs that have a strong therapeutic and commercial fit with our current portfolio.

Development and commercial partnership

By signing development agreement to develop our product outside EU territories.

Commercial partners and distributors

By developing a network of commercial partners and distributors to maximize the potential of our registered products.

 submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease.